Ifosfamide or trofosfamide in patients with intraocular lymphoma

Kristoph Jahnke, Eckhard Thiel, Nikolaos E. Bechrakis, Gregor Willerding, D. Kraemer, Lars Fischer, Agnieszka Korfel

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalJournal of Neuro-Oncology
Volume93
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Intraocular Lymphoma
Ifosfamide
Disease-Free Survival
Survival
Cytostatic Agents
trofosfamide
Lymphoma
Therapeutics
Recurrence

Keywords

  • Ifosfamide
  • Intraocular lymphoma
  • Primary CNS lymphoma
  • Trofosfamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Jahnke, K., Thiel, E., Bechrakis, N. E., Willerding, G., Kraemer, D., Fischer, L., & Korfel, A. (2009). Ifosfamide or trofosfamide in patients with intraocular lymphoma. Journal of Neuro-Oncology, 93(2), 213-217. https://doi.org/10.1007/s11060-008-9761-8

Ifosfamide or trofosfamide in patients with intraocular lymphoma. / Jahnke, Kristoph; Thiel, Eckhard; Bechrakis, Nikolaos E.; Willerding, Gregor; Kraemer, D.; Fischer, Lars; Korfel, Agnieszka.

In: Journal of Neuro-Oncology, Vol. 93, No. 2, 2009, p. 213-217.

Research output: Contribution to journalArticle

Jahnke, K, Thiel, E, Bechrakis, NE, Willerding, G, Kraemer, D, Fischer, L & Korfel, A 2009, 'Ifosfamide or trofosfamide in patients with intraocular lymphoma', Journal of Neuro-Oncology, vol. 93, no. 2, pp. 213-217. https://doi.org/10.1007/s11060-008-9761-8
Jahnke, Kristoph ; Thiel, Eckhard ; Bechrakis, Nikolaos E. ; Willerding, Gregor ; Kraemer, D. ; Fischer, Lars ; Korfel, Agnieszka. / Ifosfamide or trofosfamide in patients with intraocular lymphoma. In: Journal of Neuro-Oncology. 2009 ; Vol. 93, No. 2. pp. 213-217.
@article{3a23320a30a64c9991ad299f3ba9265c,
title = "Ifosfamide or trofosfamide in patients with intraocular lymphoma",
abstract = "We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.",
keywords = "Ifosfamide, Intraocular lymphoma, Primary CNS lymphoma, Trofosfamide",
author = "Kristoph Jahnke and Eckhard Thiel and Bechrakis, {Nikolaos E.} and Gregor Willerding and D. Kraemer and Lars Fischer and Agnieszka Korfel",
year = "2009",
doi = "10.1007/s11060-008-9761-8",
language = "English",
volume = "93",
pages = "213--217",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Ifosfamide or trofosfamide in patients with intraocular lymphoma

AU - Jahnke, Kristoph

AU - Thiel, Eckhard

AU - Bechrakis, Nikolaos E.

AU - Willerding, Gregor

AU - Kraemer, D.

AU - Fischer, Lars

AU - Korfel, Agnieszka

PY - 2009

Y1 - 2009

N2 - We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.

AB - We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.

KW - Ifosfamide

KW - Intraocular lymphoma

KW - Primary CNS lymphoma

KW - Trofosfamide

UR - http://www.scopus.com/inward/record.url?scp=67349239314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349239314&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9761-8

DO - 10.1007/s11060-008-9761-8

M3 - Article

C2 - 19099202

AN - SCOPUS:67349239314

VL - 93

SP - 213

EP - 217

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -